Fatty acid amide hydrolase: A potential target for next generation therapeutics

Current Pharmaceutical Design

Volumn 12, Issue 6, 2006, Pages 759-772

  Maccarrone, Mauro ^a,b,c  

^a UNIVERSITY OF TERAMO   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c Center for Experimental Neurobiology   (Italy)

Author keywords

Cannabinoid receptor; Endocannabinoid; Enzyme inhibitor; Gene promoter; Hydroperoxide; Lipoxygenase; Metabolism; Vanilloid receptor

Indexed keywords

15 HYDROPEROXYARACHIDONIC ACID; 2 ARACHIDONOYLGLYCEROL; AMIDE; ANANDAMIDE; ARACHIDONOYLDIAZOMETHYLKETONE; ARACHIDONOYLSEROTONIN; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABIS; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DELTA9 OCTADECEYNOIL ALPHA KETO OXAZOLOPYRIDINE; DRONABINOL; ENDOCANNABINOID; ESTER; FATTY ACID AMIDASE; HYDROLASE INHIBITOR; MEMBRANE PROTEIN; METHYLARACHIDONOYLFLUOROPHOSPHONATE; N OLEOYLETHANOLAMINE; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; POLYUNSATURATED FATTY ACID; PROPOFOL; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VIRODHAMINE; AMIDASE; ENZYME INHIBITOR; FATTY-ACID AMIDE HYDROLASE;

ANESTHESIA; ANXIETY; CELL TRANSPORT; CHEMICAL STRUCTURE; COLORECTAL CANCER; DRUG STRUCTURE; DRUG TARGETING; ENZYME DEGRADATION; ENZYME STRUCTURE; INFERTILITY; LYMPHOMA; MEMBRANE TRANSPORT; NEUROLOGIC DISEASE; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; PROMOTER REGION; RAT; REVIEW; TRANQUILIZING ACTIVITY; ANIMAL; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM DISEASE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; METABOLISM; METHODOLOGY;

AMIDOHYDROLASES; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CHEMISTRY, PHARMACEUTICAL; ENDOCANNABINOIDS; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE;

EID: 33645299083     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775474279     Document Type: Review

References (130)

1. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
2. Di Marzo V, Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: "killing two birds with one stone". Prostaglandins Leukot Essent Fatty Acids 1995; 53: 1-11.
3. Meehoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 2002; 8: 58-61.
4. Maccarrone M, Finazzi-Agrò A. Endocannabinoids and their actions. Vitam Horm 2002; 65: 225-55.
5. Sugiura 7, Kobayashi Y, Oka S, Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 173-92.
6. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004; 141: 765-74.
7. Van der Stelt M, Van Kuik JA, Bari M, van Zadelhoff G, Leeflang BR, Veldink GA, et al. Oxygenated metabolites of anandamide and 2-arachidonoyl-glycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter and fatty acid amide hydrolase. J Med Chem 2002; 45: 3709-20.
8. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 101-21.
9. 1 receptor. Proc Natl Acad Sci USA 2001; 98: 3662-5.
10. Oka S, Tsuchie A, Tokumura A, Muramatsu M, Suhara Y, Takayama H, et al. Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J Neurochem 2003; 85: 1374-81.
11. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 recepton. J Pharmacol Exp Ther 2002; 301: 1020-4.
12. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 1998; 353: 23-31.
13. Lambert DM, Di Matzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem 1999; 6: 757-73.
14. Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M. et al, Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide, in human cancer cells. Biochem J 2001; 358: 249-55.
15. MacDonald JC, Vaughan CW. Cannabinoids act backwards. Nature 2001; 410: 527-30.
16. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296: 678-82.
17. Maccarrone M, Attinà M, Cartoni A, Bari M. Finazzi-Agrò A. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J Neurochem 2001; 716: 594-601.
18. Maccarrone M, Bisogno T, Valensise H, Lazzarin N, Fezza F, Manna C, et al. Low fatty acid amide hydrolase and high anandamide levels are associated with Failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol Hum Reprod 2002; 8: 188-95.
19. Koutek B, Prestwich GD, Howlett AC, Chin SA, Salehani D, Akhavan N, et al. Inhibitors or arachidonoyl ethanolamide hydrolysis. J Biol Chem 1994; 269: 22937-40.
20. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol pharmacol 2001; 155-63.
21. Piomelli D. The molecular logic of endocannabinoid signalling. Nature Rev Neurosci 2003; 4: 873-84.
22. Howlett AC, Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids 2000; 108: 53-70.
23. Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur J Pharmacol 2003; 461: 27-34.
24. Jung J, Hwang SG, Kwak J, Lee SY, Kang CJ, Kim WB, et al. Capsaicin binds to the intracellular domain of the capsaicin-activated ion channel. J Neurosci 1999; 19: 529-38.
25. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanism. Pharmacol Rev 1999; 51: 159-212.
26. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agrò A, Di Marzo V, The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 2001; 276: 12856-63.
27. Van der Stelt M, Di Marzo V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 2004; 271: 1827-34.
28. Jordt SE, Julius D. Molecular basis for species-specific sensitivity to "hot" chili peppers. Cell 2002; 108: 421-30.
29. Maccarrone M, Finazzi-Agrò A. The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ 2003; 10: 946-55.
30. Yamaji K, Sarker KP, Kawahara K, Iino S, Yamakuchi M, Abeyama K, et al. Anandamide induces apoptosis in human endothelial cells: its regulation system and clinical implications. Thromb Haemost 2003; 89: 875-84.
31. Mezey E, Toth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, et al. Distribution of mRNA for vanilloid receptor subtype 1 VR1 and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 2000; 97: 3655-60.
32. Bisogno T, Melck D, Bobrov MYu, Gretskaya NM, Bezuglov VV, De Petrocellis L, et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000; 3: 817-24.
33. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002; 92: 8400-5.
34. Kruszka KK, Gross RW. The ATP- and CoA-independent synthesis of arachidonoylethanolamide. A novel mechanism underlying the synthesis of the endogenous ligand of the cannabinoid receptor. J Biol Chem 1994; 269: 14345-8.
35. Devane WA, Axelrod J. Enzymatic synthesis or anandamide, an endogenous ligand for the cannabinoid recepior, by brain membranes. Proc Natl Acad Sci USA 1994: 91: 6698-701.
36. Kurahashi Y, Ueda N, Sazuki H, Suzuki M, Yamamoto, S. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty acid amide hydrolase, Biochem Biophys Res Commun 1997; 237: 512-5.
37. Hansen HH, Hansen SH, Schousboe A, Hansen HS. Determination of the phospholipid precursor of anandamide and other N-acylethanolamine phospholipids before and after sodium azide-induced toxicity in cultured neocortical neurons. J Neurochem 2000; 75: 861-71.
38. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and Its congeners. J Biol Chem 2004; 279: 5298-305.
39. Hillard CJ, Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 2003; 140: 802-8.
40. Nogawa S, Forster C, Zhang F, Nagayama M, Ross ME, Iadecola C. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc Natl Acad Sci USA l998; 95: 10966-71.
41. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB. Accumulation of N-arachidonoylethanolamide (anadamide) into cerebullar granule cells occurs via facilitated diffusion. J Neurochem 1997; 69: 631-8.
42. Maccarrone M, Bari M, Battista N. Finazzi-Agrò A. Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood 2002; 100: 4040-8.
43. Ligresti A, Morera E, Van der Stelt M, Monory K, Lutz B, Ortar G, et al, Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J 2004; 380: 265-72.
44. Bisogno T, De Petrocellis L, Di Marzo V. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des 2002; 8: 533-47.
45. Cravatt BF, Lichtman AH, Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 2003; 7: 469-75.
46. Van der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 2003; 480: 133-50.
47. Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 2002; 298: 1793-6.
48. Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolase. Proc Natl Acad Sci USA 1997; 94: 2238-42.
49. Bisogno T, Ventriglia M, Milone A, Mosca M, Cimino G, Di Marzo V. Occurrence and metabolism of anatidamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Biochim Biophys Acta 1997; 1345: 338-48.
50. Sepe N, De Petrocellis L, Montanaro F, Cimino G, Di Marzo V. Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Possible implications for mollusc physiology and sea food industry. Biochim Biophys Acta 1998; 1389:101-11.
51. De Petrocellis L, Melck D, Bisogno T, Milone A, Di Marzo V. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience 1999; 92: 377-87.
52. Shrestha R, Dixon RA, Chapman KD. Molecular identification of a functional homologue of the mammalian fatty acid amide hydrolase in Arabidopsis thaliana. J Biol Chem 2003; 278: 34990-7.
53. McPartland J, Di Marzo V, De Petrocellis L, Mercer A, Glass M. Cannabinoid receptors are absent in insects. J Comp Neurol 2001; 436: 423-9.
54. McKinney MK, Cravatt BF. Evidence for distinct roles in catalysis for residues of the serine-serine-lysine catalytic triad of fatty acid amide hydrolase. J Biol Chem 2003; 278: 37393-9.
55. Leung D, Hardouin C, Boger DL, Cravatt BF. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat Biotechnol 2003; 21: 687-91.
56. Deutsch DG, Glaser ST, Howell JM, Kunz JS, Puffenharger RA, Hillard CJ, et al. The cellular uptake of anandamide, is coupled to its breakdown by fatty acid amide hydrolase (FAAH). J Biol Chem 2001; 276: 6967-73.
57. Glaser ST, Abumrad NA, Fatade F. Kaczocha M, Studholme KM, Deutsch DG. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 2003; 100: 4269-74.
58. Basavarajappa BS, Saito M, Cooper TB, Hungund BL, Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons. Eur J Pharmacol 2003; 466: 73-83.
59. Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Fowler CJ, Tiger G, de Lago E, et al. Design, synthesis, and biological evaluation or new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J Med Chem 2003; 46: 1512-22.
60. Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 2003; 65: 1473-81.
61. Fegley D, Kathuria S. Mercier R, Li C, Goutopoulos A, Makriyannis A, Piomelli D. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA 2004; 101: 8756-61.
62. Ortega-Gutierrez S, Hawkins EG, Viso A, Lopez-Rodriguez ML, Cravatt BF. Comparison of anandamide transport in FAAH wild-type and knockout neurons: Evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry 2004; 43: 8184-90.
63. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-6.
64. Iversen L. Cannabis and the brain. Brain 2003; 126: 1252-70.
65. Di Carlo G, Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs 2003; 12: 39-49.
66. Fowler CJ, Jonsson K-O, Tiger G. Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoyethanolamide, and oleamide, Biochem Pharmacol 2001; 62: 517-26.
67. Deutsch DG, Omeir R, Arreaza G, Salehani D, Prestwich GD, Huang Z, et al. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem Pharmacol 1997; 53: 255-60.
68. Bisogno T, Melck D, De Petrocellis L, Bobrov MYu, Gretskaya NM, el al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 1998; 248: 515-22.
69. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, et al. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide, Proc Natl Acad Sci USA 2000; 97: 5044-9.
70. Kathuria S, Gaetani S, Fegley D, Valino, F, Duranti A, Tontini A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nature Med 2003; 9: 76.
71. Gaetani S, Cuomo V, Piomelli D. Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med 2003; 9: 474-8.
72. Martin BR, Beletskaya I, Patrick G, Jefferson R, Winckler R, Deutsch DG, et al. Cannabinoid properties of methylfluorophosphonate analogs. J Pharmacol Exp Ther 2000; 294: 1209-18.
73. Patel S, Wohlfeil ER, Rademacher DJ, Carrier EJ, Perry LJ, Kundu A, et al. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol 2003; 139: 1005-13.
74. Di Marzo V. Manipulation of the endocannabinoid system by a general anaesthetic. Br J Pharmacol 2003; 139: 885-6.
75. Maccarrone M, Inhibition of anandamide hydrolysis: cells also know how to do it. Trends Mol Med 2004; 10: 13-4.
76. Bornheim LM, Kim KY, Chen B, Correia MA. Microsomal cytochrome P450-mediated liver and brain anandamide metabolism. Biochem Pharmacol 1995; 50: 677-86.
77. Ross RA, Craib SJ, Stevenson LA, Pertwee RG, Henderson A, Toole J, et al. Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther 2002; 301: 900-7.
78. 2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 1997; 272: 21181-6.
79. Pinto JC, Potie F, Rice KC, Boring D, Johnson MR, Evans DM, et al. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol Pharmacol 1994; 46: 516-22.
80. Kozak KR, Crews B, Morrow JD, Wang LH, Ma YH, Weinander R, et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters ethanolamides. J Biol Chem 2002; 277: 44877-85.
81. Maccarrone M, Van der Stelt M, Veldink GA, Finazzi-Agrò A. Inhibitors of endocannabinoid degradation as potential therapeutic agents. Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents 2002; 1: 103-13.
82. Matias I, Chen J, De Petrocellis L, Bisogno T, Ligresti A, Fezza F, et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther 2004; 309: 745-57.
83. Huang SM, Bisogno T, Petros TJ, Chang SY, Zavitsanos PA, Zipkin RE, et al. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 2001; 276: 42639-44.
84. Burstein SH, Huang SM, Petros TJ, Rossetti RG, Walker JM, Zurrier. RB. Regulation of anandamide tissue levels by N-arachidonylglycine. Biochem Pharmacol 2002; 64: 1147-50.
85. Ueda N, Yamamoto K, Yamamoto S, Tokunaga T, Shirakawa E, Shinkai H, et al. Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochim Biophys Acta 1995; 1254: 127-134.
86. Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonyl-ethanolamide (anandamide): Their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 1998; 54: 180-8.
87. Kozak KR, Gupta RA, Moody JS, Ji C, Boeglin WE, DuBois RN, et al. 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem 2002; 277: 23278-86.
88. Kozak KR, Prusakiewicz JJ, Rowlinson SW, Prudhomme DR, Marnett LJ. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid anandamide. Biochemistry 2003; 42: 9041-9.
89. Veldhuis WB, Van der Stelt M, Wadman MW, Van Zadelhoff G, Maccarrone M, Fezza F, et al. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J Neurosci 2003; 23: 4127-33.
90. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003; 302: 84-8.
91. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 2002; 42: 11S-9S.
92. Bifulco M, Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med. 2002; 8: 547-50.
93. 2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2002; 100: 627-34.
94. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003; 125: 677-87.
95. Maccarrone M, Fiorucci L, Erba F, Bari M, Finazzi-Agrò A, Ascoli F. Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase, and do not express cannabinoid receptors. FEBS Lett 2000; 468: 176-80.
96. Craib SJ, Ellington HC, Pertwee RG, Ross RA. A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br J Pharmacol 2001; 134: 30-7.
97. Thomas BF, Adams IB, Mascarella SW, Martin BR, Razdan RK. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J Med Chem 1996; 39: 471-9.
98. Tong W, Collantes ER, Welsh WJ, Berglund BA, Howlett AC. Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis. J Med Chem 1998; 41: 4207-15.
99. Khanolkar AD, Palmer SL, Makriyannis A. Molecular probes for the cannabinoid receptors. Chem Phys Lipids 2000; 108: 37-52.
100. Salo 0MH, Lahtela-Kakkonen M, Gynther J, Järvinen T, Poso A. Development of a 3D model for the human cannabinoid CB1 receptor. J Med Chem 2004; 47: 3048-57.
101. Fichera M, Cruciani G, Bianchi A, Musumarra G. A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors. J Med Chem 2000; 43: 2300-9.
102. Reggio PH, Traore H. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem Phys Lipids 2000; 108: 15-35.
103. Gurwitz D, Weizman A. Fatty acid amide hydrolase inhibitors and the marijuana debate. Lancet 2001; 358: 1548.
104. Walker JM, Huang SM. Endocannabinoids in pain modulation. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 235-42.
105. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003; 11: 137-43.
106. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998; 75: 111-9.
107. Melck D, Bisogno T, De Petrocellis L, Beaulieu P, Rice AS, Di Marzo V. Cannabimimetic eicosanoids in cancer and inflammation: an update. Adv Exp Med Biol 2002; 507: 381-6.
108. Parolaro D, Massi P, Rubino T, Monti E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids, 2002; 60: 319-32.
109. Van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JFG, Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001; 21: 6475-9.
110. Piccinni MP, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat Med 1998; 4: 1020-4.
111. Sharkey A. Cytokines and implantation. Rev Reprod 1998; 3: 52-61.
112. Maccarrone M, Finazzi-Agrò A. Anandamide hydrolase: a guardian angel of human reproduction? Trends Pharmacol Sci 2004; 25: 353-7.
113. Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agrò A. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 2000; 355: 1326-9.
114. Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agrò A. Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility. J Immunol 2001; 166: 7183-9.
115. Maccarrone M, Falciglia K, Di Rienzo M, Finazzi-Agrò A. Endocannabinoids, hormone-cytokine networks and human fertility. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 309-17.
116. Lazzarin N, Valensise H, Bari M, Ubaldi F, Battista N, Finazzi-Agrò A, et al. Fluctuations of fatty acid amide hydrolase and anandamide levels during the human ovulatory cycle. Gynecol Endocrinol 2004; 18: 212-18.
117. Piomelli D. THC: moderation during implantation. Nat Med 2004; 10: 19-20.
118. 9-tetrahydrocannabinol modulation of sexual receptivity in female rats, Proc Natl Acad Sci USA 2001; 98: 1249-54.
119. Paria BC, Dey SK. Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation. Chem Phys Lipids 2000; 108: 211-20.
120. Paria BC, Song H, Wang X, Schmid PC, Krebsbach RJ, Schmid HH, et al. Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation. J Biol Chem 2001; 276: 20523-28.
121. Paria BC, Dey SK, Embryonic cannabinoid receptors are targets for natural and endocannabinoids during early pregnancy. In: Onaivi ES Ed, Biology of Marijuana: from gene to behavior. London, Taylor & Francis 2002; 344-55.
122. Maccarrone M, Bari M, Di Rienzo M, Finazzi-Agrò A, Rossi A. Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros. Evidence for a synergistic effect of leptin. J Biol Chem 2003; 278: 32726-32.
123. Ahima RS, Flier JS, Leptin. Annu Rev Physiol 2000; 62: 413-37.
124. Matarese G, La Cava A, Sanna V, Lord GM, Lechler RI, Fontana S, et al. Balancing susceptibility to infection and autoimmunity: a role for leptin? Trends Immunol 2002; 23: 182-7.
125. Maccarrone M, Di Rienzo M, Finazzi-Agrò A, Rossi A. Leptin activates the anandamide hydrolase promoter in human T lymphocyte through STAT3. J Biol Chem 2003; 278: 13318-24.
126. Maccarrone M, De Felici M, Klinger FG, Battista N, Fezza F, Dainese E, et al. Mouse blastocysts release a lipid which activates anandamide hydrolase in intact uterus. Mol Hum Reprod 2004; 10: 215-21.
127. Schuel H, Burkman LJ, Lippes J, Lippes J, Crickard K, Mahony MC, Guiffrida A, et al. Evidence that anandamide-signaling regulates human sperm functions required for fertilization. Mol Reprod Dev 2002; 63: 376-87.
128. Guzman M. Cannabinoids: Potential anticancer agents. Nat Rev Cancer 2003; 3: 745-55.
129. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002; 99: 10819-24.
130. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid sugnaling in the brain. J Cell Biol 2003; 163: 463-8.